|Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.|
|Jump to Full Text|
|PMID: 23143746 Owner: NLM Status: MEDLINE|
|Antigen-specific cancer immunotherapy is a promising strategy for improving cancer treatment. Recently, many tumor-associated antigens and their epitopes recognized by cytotoxic T lymphocytes (CTLs) have been identified. However, the density of endogenously presented antigen-derived peptides on tumor cells is generally sparse, resulting in the inability of antigen-specific CTLs to work effectively. We hypothesize that increasing the density of an antigen-derived peptide would enhance antigen-specific cancer immunotherapy. Here, we demonstrated that intratumoral peptide injection leads to additional peptide loading onto major histocompatibility complex class I molecules of tumor cells, enhancing tumor cell recognition by antigen-specific CTLs. In in vitro studies, human leukocyte antigen (HLA)-A*02:01-restricted glypican-3144-152 (FVGEFFTDV) and cytomegalovirus495-503 (NLVPMVATV) peptide-specific CTLs showed strong activity against all peptide-pulsed cell lines, regardless of whether the tumor cells expressed the antigen. In in vivo studies using immunodeficient mice, glypican-3144-152 and cytomegalovirus495-503 peptides injected into a solid mass were loaded onto HLA class I molecules of tumor cells. In a peptide vaccine model and an adoptive cell transfer model using C57BL/6 mice, intratumoral injection of ovalbumin257-264 peptide (SIINFEKL) was effective for tumor growth inhibition and survival against ovalbumin-negative tumors without adverse reactions. Moreover, we demonstrated an antigen-spreading effect that occurred after intratumoral peptide injection. Intratumoral peptide injection enhances tumor cell antigenicity and may be a useful option for improvement in antigen-specific cancer immunotherapy against solid tumors.|
|Daisuke Nobuoka; Toshiaki Yoshikawa; Mari Takahashi; Tatsuaki Iwama; Kazutaka Horie; Manami Shimomura; Shiro Suzuki; Noriko Sakemura; Munehide Nakatsugawa; Hiroshi Sadamori; Takahito Yagi; Toshiyoshi Fujiwara; Tetsuya Nakatsura|
Related Documents :
|11043396 - Study of immortalization and malignant transformation of human embryonic esophageal epi...
10566806 - Effects of a controlled-release cisplatin delivery system used after resection of mamma...
9687986 - Inhibitory effects of soy and rye diets on the development of dunning r3327 prostate ad...
6219246 - A morphologic classification and incidence of alveolar-bronchiolar neoplasms in balb/c ...
17544696 - Stereotactic radiation techniques in the treatment of acoustic schwannomas.
18459106 - Expression of micrornas and protein-coding genes associated with perineural invasion in...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-11-11|
|Title: Cancer immunology, immunotherapy : CII Volume: 62 ISSN: 1432-0851 ISO Abbreviation: Cancer Immunol. Immunother. Publication Date: 2013 Apr|
|Created Date: 2013-04-12 Completed Date: 2013-06-07 Revised Date: 2013-07-11|
Medline Journal Info:
|Nlm Unique ID: 8605732 Medline TA: Cancer Immunol Immunother Country: Germany|
|Languages: eng Pagination: 639-52 Citation Subset: IM|
|Division of Cancer Immunotherapy, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.|
|APA/MLA Format Download EndNote Download BibTex|
Cell Line, Tumor
Colonic Neoplasms / immunology, therapy
Epitopes, T-Lymphocyte / immunology*
HLA-A Antigens / immunology*
Hep G2 Cells
Immunotherapy / methods*
Liver Neoplasms / immunology, therapy
Lymphoma / immunology, therapy
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Inbred NOD
Peptide Fragments / administration & dosage*, immunology*
T-Lymphocytes, Cytotoxic / immunology*
|0/Epitopes, T-Lymphocyte; 0/HLA-A Antigens; 0/Peptide Fragments|
Journal ID (nlm-ta): Cancer Immunol Immunother
Journal ID (iso-abbrev): Cancer Immunol. Immunother
Publisher: Springer-Verlag, Berlin/Heidelberg
© The Author(s) 2012
Received Day: 29 Month: 6 Year: 2012
Accepted Day: 29 Month: 10 Year: 2012
Electronic publication date: Day: 11 Month: 11 Year: 2012
pmc-release publication date: Day: 11 Month: 11 Year: 2012
Print publication date: Month: 4 Year: 2013
Volume: 62 Issue: 4
First Page: 639 Last Page: 652
PubMed Id: 23143746
Publisher Id: 1366
|Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy|
Address: +814-7131-5490 +814-7133-6606 email@example.com
Division of Cancer Immunotherapy, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577 Japan
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 Japan
Conventional modalities of cancer treatment, including surgery, radiotherapy, and chemotherapy, have made advancements in recent years, and the survival rate of cancer patients has gradually improved; however, these therapies remain far from being satisfactory in most cancers [1, 2]. Therefore, the development of novel treatment modalities, including antigen-specific cancer immunotherapies with peptide vaccines, dendritic cell vaccines, and adoptive cell transfer therapies, is critical for advancing effective cancer treatments [3–5]. While many tumor-associated antigens and epitopes recognized by cytotoxic T lymphocytes (CTLs) have been explored as possible antigen-specific cancer immunotherapies, the results of several anticancer immunotherapy clinical trials have been disappointing [6, 7]. We conducted a clinical trial using the glypican-3 (GPC3) peptide vaccine in advanced hepatocellular carcinoma (HCC) patients. While this carcinoembryonic antigen overexpressed in HCC seemed to be an ideal target for anticancer immunotherapy [8–15], only immunological efficacy was apparent , whereas the clinical benefit was limited in patients . Therefore, the establishment of an innovative strategy to link the antitumor immune response with the clinical response and to enhance the power of antigen-specific cancer immunotherapy is urgently required.
In the antigen-specific cancer immunotherapy concept, antigen-specific CTLs recognize and destroy tumor cells that present antigen-derived peptides using cell surface major histocompatibility complex (MHC) class I molecules. However, the density of the antigen-derived peptide endogenously presented on tumor cells is generally low, resulting in the ineffectiveness of antigen-specific CTLs . This low density of presented antigen is one reason why antigen-specific cancer immunotherapy has been ineffective in clinical settings. One solution for overcoming this critical problem is to induce high-avidity CTLs. Such CTLs can recognize a smaller number of peptide–MHC class I complexes and would contribute to a better outcome . Another solution is to enhance tumor cell antigenicity by means of additional peptide loading onto MHC class I molecules. Increasing the density of antigen-derived peptide would facilitate CTL recognition and destruction of the tumor cells.
In this study, we investigated whether intratumoral peptide injection would induce additional peptide loading onto tumor cells, and, if so, whether increased presentation would enhance antigen-specific CTL tumor cell recognition. Moreover, we evaluated whether intratumoral peptide injection could be a useful option for improvement in antigen-specific cancer immunotherapy against solid tumors.
The peptides used in this study were as follows: human leukocyte antigen (HLA)-A*02:01-restricted GPC3144–152 (FVGEFFTDV) peptide (American Peptide Company, Sunnyvale, CA), HLA-A*24:02-restricted GPC3298–306 (EYILSLEEL) peptide (American Peptide Company), HLA-A*02:01-restricted cytomegalovirus (CMV)495–503 (NLVPMVATV) peptide (ProImmune, Rhinebeck, NY, USA), HLA-A*24:02-restricted CMV341–349 (QYDPVAALF) peptide (ProImmune), HLA-A*02:01-restricted human immunodeficiency virus (HIV)77–85 (SLYNTYATL) peptide (ProImmune), and H-2 Kb-restricted ovalbumin (OVA)257–264 (SIINFEKL) peptide (AnaSpec, Fremont, CA, USA). The peptides were dissolved and diluted in 7 % NaHCO3.
T2 cells (HLA-A*02:01), which lack the transporter associated with antigen processing (TAP), were purchased from Riken Cell Bank (Tsukuba, Japan). The human liver cancer cell line HepG2 (GPC3+, HLA-A*02:01/A*24:02) was purchased from American Type Culture Collection (Manassas, VA, USA). The human liver cancer cell line SK-Hep-1 (GPC3−, HLA-A*02:01/A*24:02), human colon cancer cell line SW620 (GPC3−, HLA-A*02:01/A*24:02), murine lymphoma cell line RMA (OVA−, H-2 Kb), EL4 (OVA−, H-2 Kb), and EG7 (OVA+, H-2 Kb) were kindly provided by Dr. Yasuharu Nishimura (Kumamoto University, Kumamoto, Japan). SK-Hep-1/GPC3 is an established stable GPC3-expressing cell line transfected with a human GPC3 gene, and SK-Hep-1/vec is an established counterpart cell line, in which an empty vector was transfected. EG7 cells are OVA-transfected EL4 cells. Cells were cultured at 37 °C in RPMI 1640 or DMEM medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10 % fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin in a humidified atmosphere containing 5 % CO2.
Female BALB/c nude, NOD/SCID, and C57BL/6 mice (6–8 weeks old) were purchased from Japan Charles River Laboratories (Yokohama, Japan). OT-I mice , which are CD8+ T-cell TCR transgenic mice expressing the TCR α-chain recognizing OVA257–264 peptide in H-2 Kb, were kindly provided by Dr. Takashi Nishimura (Hokkaido University, Sapporo, Japan). All animal procedures were performed according to the guidelines for the Animal Research Committee of the National Cancer Center, Japan.
Naïve CD8+ T-cells were purified from the spleens of OT-I mice using MACS anti-CD8a (Ly-2) MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany). For in vitro activation, naïve OT-I CD8+ T-cells were incubated with irradiated EG7 cells at a 3:2 ratio in 24-well plates for 3 days. Each well contained 2.4 × 106 OT-I CD8+ T-cells plus 1.6 × 106 EG7 cells in 2 ml of RPMI 1640 medium supplemented with 10 % FBS, penicillin, streptomycin, and 50 μmol/l 2-mercaptoethanol. Activated OT-I CD8+ T-cells were separated from EG7 cells using anti-CD8a magnetic beads before adoptive transfer.
The BD™ ELISPOT set (BD Biosciences, San Jose, CA, USA) was used for an interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay. CTLs were used as effector cells, and tumor cell lines with or without a peptide pulse (10 μg/ml for 1 h) were used as target cells. Effector cells (1 × 103/well) were incubated with target cells (1 × 104/well) in 200 μl of RPMI 1640 medium supplemented with 10 % FBS, penicillin, and streptomycin for 20 h at 37 °C in 5 % CO2. The number of spots, indicating an antigen-specific CTL response, was automatically counted using the Eliphoto system (Minerva Tech, Tokyo, Japan).
The Terascan VPC system (Minerva Tech) was used for cytotoxicity assays. Target cells were labeled with Calcein-AM (Dojindo Laboratories, Kumamoto, Japan) solution for 30 min at 37 °C, washed three times, distributed to 96-well culture plates in duplicate, and incubated with effector cells for 4 h. Fluorescence intensity was measured before and after the 4-h culture, and antigen-specific cytotoxic activity was calculated as described previously .
In in vivo studies, tumors implanted on the backs of mice were injected with 50 μg peptide mixed with an equal volume of incomplete Freund’s adjuvant (IFA, Montanide ISA-51VG; SEPPIC, Paris, France). The total volume of solution injected was 100 μl in all experiments.
To investigate whether the injected peptide was loaded onto HLA class I molecules of tumor cells in a solid mass, an IFN-γ ELISPOT assay was performed using these isolated tumor cells as target cells. Mice were killed and their dorsal tumors were dissected, cut into small pieces, and digested with collagenase (1.5 mg/ml) for 20 min at 37 °C.
In a peptide vaccine model, H-2 Kb-restricted OVA257–264 peptide emulsified with IFA (50 μg/100 μl) was intradermally injected at the base of the tail of C57BL/6 mice, five times at 7-day intervals as described previously . After vaccination, the induction of H-2 Kb-restricted OVA257–264 peptide-specific CTLs was detected by IFN-γ ELISPOT assay (data not shown). In an adoptive transfer model, activated OT-I CTL (1 × 107 cells/500 μl) was intravenously injected.
SW620 cells (5 × 106 cells/100 μl) were subcutaneously implanted into the backs of BALB/c nude mice; SK-Hep-1/vec, SK-Hep-1/GPC3, or HepG2 cells (5 × 106 cells/100 μl) were implanted into NOD/SCID mice, and RMA cells (5 × 104 or 5 × 105 cells/100 μl) were implanted into C57BL/6 mice. Tumor volume was monitored twice a week and calculated using the following formula: tumor volume (mm3) = a × b2 × 0.5, where a is the longest diameter, b is the shortest diameter, and 0.5 is a constant to calculate the volume of an ellipsoid. Mortality and morbidity were checked daily, and the mice were maintained until each mouse showed signs of morbidity or the length or width of the tumors exceeded 30 mm, at which point they were killed for reasons of animal welfare.
For the analysis of local accumulation of antigen-specific CTLs, isolated tumor cells, including tumor-infiltrating lymphocytes, were stained with H-2 Kb OVA Tetramer-PE (OVA257–264 [SIINFEKL]; MBL, Nagoya, Japan) for 20 min at room temperature and anti-mouse CD8-FITC (rat monoclonal, clone KT15; MBL) for 20 min at 4 °C. Flow cytometry analysis was carried out using a FACSCanto II flow cytometer (BD Biosciences).
To investigate whether CD8+ T-cells infiltrated normal tissues due to intratumoral peptide injection in a murine adoptive cell transfer model, we performed immunohistochemical staining of CD8 in tissue specimens from C57BL/6 mice using monoclonal anti-CD8 antibody (dilution 1:20, BioLegend, San Diego, CA, USA).
Comparisons of spot numbers and tumor volume at the last time point were performed using the Mann–Whitney U test. Survival was analyzed according to the Kaplan–Meier estimate, and differences between groups were compared using the log-rank test. Differences were considered significant at P < 0.05. Data were analyzed with the statistical package, Dr. SPSS II (SPSS Japan, Tokyo, Japan).
To evaluate the antigen-specific CTL response in vitro, IFN-γ ELISPOT and cytotoxicity assays were performed. In both assays, the two types of effector cells were the HLA-A*02:01-restricted GPC3144–152 peptide-specific CTL clone, which was established from peripheral blood mononuclear cells (PBMCs) of an HCC patient who had received the GPC3144–152 peptide vaccine , and the HLA-A*02:01-restricted CMV495–503 peptide-specific CTL clone, which was established from PBMCs of a healthy volunteer. The target cells were tumor cell lines with or without antigenic peptide pulses.
As shown in Fig. 1a, in an IFN-γ ELISPOT assay, the HLA-A*02:01-restricted GPC3144–152 peptide-specific CTLs produced IFN-γ in the presence of GPC3-expressing tumor cells, HepG2 and SK-Hep-1/GPC3, without peptide pulse. These effector cells recognized GPC3144–152 antigen peptide, which is endogenously presented on the cell surface of the non-peptide-pulsed target cells. The number of IFN-γ-producing cells increased dramatically after the pulse of HLA-A*02:01-restricted GPC3144–152 peptide. In contrast, GPC3144–152 peptide-specific CTLs did not produce IFN-γ against GPC3-negative tumor cells, SW620 and SK-Hep-1/vec, without peptide pulse. However, a marked increase in IFN-γ-producing cells was detected against these cell lines after the pulse of HLA-A*02:01-restricted GPC3144–152 peptide. The IFN-γ-producing cells did not increase after the pulse of HLA-A*24:02-restricted GPC3298–306 or HLA-A*02:01-restricted HIV77–85 peptide (Fig. 1a). Similarly, HLA-A*02:01-restricted CMV495–503 peptide-specific CTLs produced IFN-γ only in the presence of HLA-A*02:01-restricted CMV495–503 peptide-pulsed target cells (Fig. 1b).
In a cytotoxicity assay, HLA-A*02:01-restricted GPC3144–152 and CMV495–503 peptide-specific CTLs showed antigen-specific killing activity according to the peptide density on tumor cells. HLA-A*02:01-restricted GPC3144–152 peptide-specific CTLs showed specific cytotoxicity against HLA-A*02:01-restricted GPC3144–152 peptide-pulsed SW620 and T2 targets, whereas they did not show cytotoxicity against HLA-A*02:01-restricted HIV77–85 peptide-pulsed targets (Fig. 1c). In addition, HLA-A*02:01-restricted GPC3144–152 peptide-specific CTLs showed apparent but weak cytotoxicity (13–44 %) against non-peptide-pulsed HepG2 and SK-Hep-1/GPC3 cells, but the cytotoxicity was markedly strengthened (55–99 %) against all examined cell lines after the HLA-A*02:01-restricted GPC3144–152 peptide pulse (Fig. 1d). Similarly, HLA-A*02:01-restricted CMV495–503 peptide-specific CTLs showed CMV495–503 peptide-specific cytotoxicity against all examined cell lines pulsed with CMV495–503 peptide (Fig. 1e).
The peptide-specific CTLs showed strong activity against all peptide-pulsed cell lines, regardless of whether the tumor cells expressed the antigen. The density of the HLA-A*02:01-restricted GPC3144–152 peptide endogenously presented on tumor cells was not enough to induce strong CTL activity.
As shown in Fig. 2a, BALB/c nude mice were inoculated subcutaneously on their backs with SW620 (GPC3−) tumor cells. When tumor diameters reached 5–7 mm, 50 μg HLA-A*02:01-restricted GPC3144–152 peptide was injected into the tumor. After 2–96 h, the tumors were dissected, cut into small pieces, and digested with collagenase (1.5 mg/ml) for 20 min at 37 °C. To investigate whether the injected HLA-A*02:01-restricted GPC3144–152 peptide was loaded onto HLA class I molecules of tumor cells in a solid mass, an IFN-γ ELISPOT assay was performed in duplicate using these isolated tumor cells as target cells and HLA-A*02:01-restricted GPC3144–152 peptide-specific CTLs as effector cells.
Loading of HLA-A*02:01-restricted GPC3144–152 peptide onto HLA class I of tumor cells was detected (Fig. 2b). Without IFA, the density of loaded peptide gradually decreased after intratumoral peptide injection, whereas the loaded peptide density remained for 96 h after injection with IFA, suggesting that IFA is required for long-term stability of the injected peptide (Fig. 2c). Similar data were obtained with a combination of the HLA-A*02:01-restricted CMV495–503 peptide and its specific CTLs (data not shown).
We planned and executed the experimental schedule shown in Fig. 3a. Four tumors were implanted per mouse, and each tumor received a different combination of injections, as shown in Fig. 3b. From 5–7 days after tumor inoculation, mice were treated two or three times in 5-day intervals. The treatment regime was as follows: HLA-A*02:01-restricted GPC3144–152 or CMV495–503 peptide emulsified with IFA (50 μg/100 μl) was injected into a tumor, and, 2 h later, HLA-A*02:01-restricted GPC3144–152 or CMV495–503 peptide-specific human CTLs (1 × 107 cells/100 μl) were injected into the tumor.
Intratumoral injection of a combination of HLA-A*02:01-restricted GPC3144–152 peptide and its specific CTLs resulted in statistically significant tumor growth inhibition (P < 0.05) (Fig. 3c). Similarly, this treatment was effective against SK-Hep-1/vec (Fig. 3d), SK-Hep-1/GPC3 (Fig. 3e), and HepG2 (Fig. 3f) tumors. Intratumoral injection of HLA-A*02:01-restricted GPC3144–152 peptide-specific CTLs alone against GPC3-expressing tumors, SK-Hep-1/GPC3 and HepG2, was only partially effective, suggesting that the HLA-A*02:01-restricted GPC3144–152 peptide endogenously presented on SK-Hep-1/GPC3 and HepG2 tumor cells was not sufficiently dense. However, intratumoral injection of HLA-A*02:01-restricted GPC3144–152 peptide increased the peptide density and markedly enhanced CTL activity. Similarly, intratumoral injection of HLA-A*02:01-restricted CMV495–503 peptide followed by its specific CTLs resulted in statistically significant tumor growth inhibition (P < 0.05) (Fig. 3g). Intratumoral injection of a combination of antigen peptide and its specific CTLs had a significant antitumor effect.
After the induction of OVA257–264 peptide-specific CTLs by peptide vaccination (Fig. 4a) or after the adoptive transfer of OVA257–264 peptide-specific CTLs (Fig. 4c), intratumoral injection of OVA257–264 peptide was effective against RMA cells, which are OVA-negative tumor cells. The RMA tumors cells that were injected intratumorally with OVA257–264 peptide demonstrated significant tumor growth inhibition, compared with mice without intratumoral injection of OVA257–264 peptide (P < 0.05). The survival rate in the treatment group was significantly better than that in the control groups (P < 0.05) (Fig. 4b, d). The group that did not receive OVA257–264 peptide vaccine but that received intratumoral peptide injection showed a partial treatment effect (Fig. 4b).
To obtain direct evidence that intratumoral peptide injection leads to local accumulation of antigen-specific CTLs, an OVA tetramer assay was performed using an adoptive cell transfer model (Fig. 4e). Two RMA tumors were bilaterally implanted per mouse. One tumor was injected with the OVA257–264 peptide plus IFA, and the other tumor with IFA alone (Fig. 4f). As shown in Fig. 4g, the tumor that underwent both adoptive cell transfer of activated OT-I CTLs and intratumoral injection of the OVA peptide contained more OVA-specific CTLs than the other tumors. Local accumulation of OVA-specific CTLs after intratumoral injection of the OVA257–264 peptide was confirmed by OVA tetramer assay.
Neither toxic signs nor death due to intratumoral injection of the OVA257–264 peptide was observed. Moreover, to evaluate the risk of autoaggression by intratumoral peptide injection, the tissues of treated mice in an adoptive cell transfer model were pathologically examined. The spleen, brain, lung, heart, liver, kidney, and tumor were critically scrutinized, and the findings were compared with those from mice that had intratumoral injection with IFA alone. In mice treated with intratumoral injection of OVA257–264 peptide, a larger number of CD8+ T-cells had infiltrated the RMA tumor 24 days after the transfer of OT-I CTLs and 10 days after the last intratumoral injection of OVA257–264 peptide. However, the simultaneous infiltration of normal tissues by CD8+ T-cells was not observed (Fig. 4h). These results suggest that peptide from intratumoral injection did not spread into normal tissues.
Using an adoptive cell transfer model, we assessed the possibility of antigen-spreading effect after intratumoral peptide injection, as depicted in Fig. 5a. Two RMA tumors were bilaterally and metachronously implanted per mouse, and only the first tumors received intratumoral injection of the OVA257–264 peptide. The sizes of the second tumors were compared with those from mice that received intratumoral injection of IFA alone (Fig. 5b). Whereas the second tumors were established 14 days after the second tumor inoculation in three out of four control mice, all four peptide-loaded mice that had received intratumoral OVA257–264 peptide injection into their first tumor completely rejected the challenge of the second tumor, which did not receive intratumoral OVA257–264 peptide injection itself (Fig. 5c).
To confirm the hypothesis of antigen spreading, an IFN-γ ELISPOT assay was performed. RMA tumor-bearing C57BL/6 mice that had received adoptive transfer of OT-I CTLs and intratumoral injection of OVA257–264 peptide were killed, and their spleens were obtained 21 days after adoptive transfer and 7 days after the last intratumoral injection. CD8+ T-cells, isolated from the spleen cells using anti-CD8a magnetic beads, were incubated with irradiated RMA cells for 3 days. CD8+ T-cells were separated from RMA cells using anti-CD8a magnetic beads before the assay. An IFN-γ ELISPOT assay was performed in duplicate using CD8+ T-cells as effector cells and RMA cells as target cells (Fig. 5d). The mice that had received intratumoral injection of OVA257–264 peptide showed a significant response to OVA-negative RMA tumor cells compared with control mice that had received intratumoral injection of IFA alone (P < 0.05). The observed induction of RMA-derived antigen-specific CTLs provides evidence that antigen spreading occurred by treatment with intratumoral OVA257–264 peptide and intravenous OT-I CTLs (Fig. 5e).
We demonstrated that intratumoral peptide injection leads to additional peptide loading onto MHC class I molecules of tumor cells, causing enhanced CTL recognition of tumor cells. It is likely that a larger number of antigen-specific CTLs infiltrate the tumors after this procedure, and tumor cells are killed more easily because CTL activity depends on the peptide density of tumor cells in an HLA class I-restricted manner. In other words, intratumoral peptide injection enhances the antigenicity of tumor cells, regardless of whether the tumor cells originally expressed the antigen. To the best of our knowledge, this is the first study to show the efficacy of intratumoral peptide injection in detail. A previous report demonstrated that peptide injection around a tumor assisted the activity of low-avidity CTLs in an immunodeficient mouse model . In addition, we demonstrated the advantage as a therapeutic modality combined with antigen-specific cancer immunotherapy without any adverse reactions associated with this procedure in mice. Intratumoral peptide injection can strengthen the efficacy of every kind of antigen-specific cancer immunotherapy and may be a useful therapeutic option.
This is the first study to describe anticancer treatment with CMV-derived peptide-specific CTLs. Virus-derived antigens, which are exogenous antigens, usually have stronger antigenicity than tumor-associated autoantigens. Therefore, virus-derived antigen-specific CTLs are easier to induce . Theoretically, every kind of antigen is applicable to our procedure unless it is expressed in healthy human cells. However, it is unclear whether post-CMV-infected lesions are safe from CMV-specific CTL cytotoxicity. Further investigations are necessary regarding the possible clinical use of exogenous antigens, such as CMV-derived peptides.
We used NaHCO3, which is known to have therapeutic effects against tumors [23, 24], as a peptide diluent. However, our data demonstrated the efficacy of intratumoral peptide injection, because control animals which underwent intratumoral injection of IFA alone or IFA plus an irrelevant peptide also received NaHCO3.
In an in vivo tumor growth inhibition assay using a peptide vaccine model, the group that did not receive the OVA257–264 peptide vaccine but that received intratumoral peptide injections showed a partial treatment effect. This indicates that intratumoral or peritumoral antigen-presenting cells recognized intratumorally injected OVA257–264 peptide and induced OVA257–264 peptide-specific CTLs after three intratumoral peptide injections. However, we showed in this study that intratumoral peptide injection attracted more OVA257–264 peptide-specific CTLs and was more effective when combined with peptide vaccines or adoptive cell transfer therapies.
A limitation of intratumoral peptide injection is its delivery method. First, immunotherapy is expected to contribute toward cancer therapy especially in the early stages or in the prevention of recurrence, in which cancer sites, the so-called “micro lesions,” are undetectable by imaging modalities. However, intratumoral peptide injection must be limited to the tumors, which are detectable by imaging modalities, and can be approached with a needle. Second, it is difficult to spread the peptides over the whole tumor by intratumoral injection, especially against large tumors. Moreover, it is difficult to approach all of the multiple tumors. This procedure might limit the ability of immunotherapy as a systemic therapy. If a novel method of delivering peptides to tumor cells selectively through a systemic route is established in the future due to advances in drug-delivery technologies, this method will become more suitable for clinical application.
Another limitation is that it requires the presence of MHC class I molecules. The potential loss of MHC class I expression in tumors would lead theoretically to the failure of this approach. Previous reports have indicated that 61–85 % of breast cancers had loss of or decreased HLA class I expression [25–27]. On the other hand, the down-regulation of HLA class I was less frequently observed in other cancers [27–30]. Before clinical application, it is necessary to select cancers in which HLA class I expression is sufficiently high.
Antigen-spreading effects have been observed following anticancer immunotherapy [31–34]. The second tumor challenge is easily rejected due to immunological memory. Therefore, we fixed the number of implanted tumor cells as the second tumors could be established. In this study, we report evidence of an antigen-spreading effect after intratumoral peptide injection. If this antigen-spreading effect is sufficiently steady and reliable, intratumoral peptide injection may even be effective against imaging-invisible or unapproachable tumors.
In conclusion, intratumoral peptide injection is an attractive strategy for enhancing tumor cell antigenicity. It can induce additional peptide loading onto tumor cells, making tumor cells more antigenic for antigen-specific CTL activity against tumor cells. Moreover, it may be a useful option for improvement in antigen-specific cancer immunotherapy against solid tumors (Fig. 6).
|CTL||Cytotoxic T lymphocyte|
|HLA||Human leukocyte antigen|
|MHC||Major histocompatibility complex|
|HIV||Human immunodeficiency virus|
|TAP||Transporter associated with antigen processing|
|FBS||Fetal bovine serum|
|IFA||Incomplete Freund’s adjuvant|
|PBMC||Peripheral blood mononuclear cell|
This work was supported in part by Health and Labor Science Research Grants for Clinical Research from the Ministry of Health, Labor, and Welfare, Japan.
The authors declare that they have no conflicts of interest.
This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
|1..||Sant M,Capocaccia R,Coleman MP,Berrino F,Gatta G,Micheli A,Verdecchia A,Faivre J,Hakulinen T,Coebergh JW,Martinez-Garcia C,Forman D,Zappone A. Cancer survival increases in Europe, but international differences remain wideEur J CancerYear: 2001371659166710.1016/S0959-8049(01)00206-411527693|
|2..||Verdecchia A,Francisci S,Brenner H,Gatta G,Micheli A,Mangone L,Kunkler I. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 dataLancet OncolYear: 2007878479610.1016/S1470-2045(07)70246-217714993|
|3..||Aarntzen EH,Figdor CG,Adema GJ,Punt CJ,de Vries IJ. Dendritic cell vaccination and immune monitoringCancer Immunol ImmunotherYear: 2008571559156810.1007/s00262-008-0553-y18618110|
|4..||Rosenberg SA,Restifo NP,Yang JC,Morgan RA,Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapyNat Rev CancerYear: 2008829930810.1038/nrc235518354418|
|5..||Perez SA,von Hofe E,Kallinteris NL,Gritzapis AD,Peoples GE,Papamichail M,Baxevanis CN. A new era in anticancer peptide vaccinesCancerYear: 20101162071208020187092|
|6..||Engell-Noerregaard L,Hansen TH,Andersen MH,Thor Straten P,Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parametersCancer Immunol ImmunotherYear: 20095811410.1007/s00262-008-0568-418719915|
|7..||Itoh K,Yamada A,Mine T,Noguchi M. Recent advances in cancer vaccines: an overviewJpn J Clin OncolYear: 200939738010.1093/jjco/hyn13219015149|
|8..||Nakatsura T,Yoshitake Y,Senju S,Monji M,Komori H,Motomura Y,Hosaka S,Beppu T,Ishiko T,Kamohara H,Ashihara H,Katagiri T,Furukawa Y,Fujiyama S,Ogawa M,Nakamura Y,Nishimura Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor markerBiochem Biophys Res CommunYear: 2003306162510.1016/S0006-291X(03)00908-212788060|
|9..||Nakatsura T,Komori H,Kubo T,Yoshitake Y,Senju S,Katagiri T,Furukawa Y,Ogawa M,Nakamura Y,Nishimura Y. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in miceClin Cancer ResYear: 2004108630864010.1158/1078-0432.CCR-04-117715623647|
|10..||Nakatsura T,Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanomaBioDrugsYear: 200519717710.2165/00063030-200519020-0000115807627|
|11..||Komori H,Nakatsura T,Senju S,Yoshitake Y,Motomura Y,Ikuta Y,Fukuma D,Yokomine K,Harao M,Beppu T,Matsui M,Torigoe T,Sato N,Baba H,Nishimura Y. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinomaClin Cancer ResYear: 2006122689269710.1158/1078-0432.CCR-05-226716675560|
|12..||Motomura Y,Senju S,Nakatsura T,Matsuyoshi H,Hirata S,Monji M,Komori H,Fukuma D,Baba H,Nishimura Y. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16–F10Cancer ResYear: 2006662414242210.1158/0008-5472.CAN-05-209016489048|
|13..||Motomura Y,Ikuta Y,Kuronuma T,Komori H,Ito M,Tsuchihara M,Tsunoda Y,Shirakawa H,Baba H,Nishimura Y,Kinoshita T,Nakatsura T. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using miceInt J OncolYear: 20083298599018425324|
|14..||Shirakawa H,Suzuki H,Shimomura M,Kojima M,Gotohda N,Takahashi S,Nakagohri T,Konishi M,Kobayashi N,Kinoshita T,Nakatsura T. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinomaCancer SciYear: 20091001403140710.1111/j.1349-7006.2009.01206.x19496787|
|15..||Shirakawa H,Kuronuma T,Nishimura Y,Hasebe T,Nakano M,Gotohda N,Takahashi S,Nakagohri T,Konishi M,Kobayashi N,Kinoshita T,Nakatsura T. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancerInt J OncolYear: 20093464965619212669|
|16..||Yoshikawa T,Nakatsugawa M,Suzuki S,Shirakawa H,Nobuoka D,Sakemura N,Motomura Y,Tanaka Y,Hayashi S,Nakatsura T. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cellsCancer SciYear: 201110291892510.1111/j.1349-7006.2011.01896.x21281401|
|17..||Sawada Y,Yoshikawa T,Nobuoka D,Shirakawa H,Kuronuma T,Motomura Y,Mizuno S,Ishii H,Nakachi K,Konishi M,Nakagohri T,Takahashi S,Gotohda N,Takayama T,Yamao K,Uesaka K,Furuse J,Kinoshita T,Nakatsura T. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survivalClin Cancer ResYear: 2012183686369610.1158/1078-0432.CCR-11-304422577059|
|18..||Chang CC,Campoli M,Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?Curr Opin ImmunolYear: 20041664465010.1016/j.coi.2004.07.01515342012|
|19..||Zeh HJ 3rd,Perry-Lalley D,Dudley ME,Rosenberg SA,Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacyJ ImmunolYear: 19991629899949916724|
|20..||Hogquist KA,Jameson SC,Heath WR,Howard JL,Bevan MJ,Carbone FR. T cell receptor antagonist peptides induce positive selectionCellYear: 199476172710.1016/0092-8674(94)90169-48287475|
|21..||Yang S,Linette GP,Longerich S,Haluska FG. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209–2 M is correlated to TCR avidityJ ImmunolYear: 200216953153912077285|
|22..||Cole DK,Pumphrey NJ,Boulter JM,Sami M,Bell JI,Gostick E,Price DA,Gao GF,Sewell AK,Jakobsen BK. Human TCR-binding affinity is governed by MHC class restrictionJ ImmunolYear: 20071785727573417442956|
|23..||Robey IF,Baggett BK,Kirkpatrick ND,Roe DJ,Dosescu J,Sloane BF,Hashim AI,Morse DL,Raghunand N,Gatenby RA,Gillies RJ. Bicarbonate increases tumor pH and inhibits spontaneous metastasesCancer ResYear: 2009152260226810.1158/0008-5472.CAN-07-557519276390|
|24..||Silva AS,Yunes JA,Gillies RJ,Gatenby RA. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasionCancer ResYear: 2009152677268410.1158/0008-5472.CAN-08-239419276380|
|25..||de Kruijf EM,van Nes JG,Sajet A,Tummers QR,Putter H,Osanto S,Speetjens FM,Smit VT,Liefers GJ,van de Velde CJ,Kuppen PJ. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancerClin Cancer ResYear: 2010161272128010.1158/1078-0432.CCR-09-184420145162|
|26..||Kaneko K,Ishigami S,Kijima Y,Funasako Y,Hirata M,Okumura H,Shinchi H,Koriyama C,Ueno S,Yoshinaka H,Natsugoe S. Clinical implication of HLA class I expression in breast cancerBMC CancerYear: 20111145410.1186/1471-2407-11-45422014037|
|27..||Torigoe T,Asanuma H,Nakazawa E,Tamura Y,Hirohashi Y,Yamamoto E,Kanaseki T,Hasegawa T,Sato N. Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissuesPathol IntYear: 20126230330810.1111/j.1440-1827.2012.02789.x22524657|
|28..||Ferris RL,Hunt JL,Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significanceImmunol ResYear: 20053311313310.1385/IR:33:2:11316234579|
|29..||Yamada N,Oizumi S,Kikuchi E,Shinagawa N,Konishi-Sakakibara J,Ishimine A,Aoe K,Gemba K,Kishimoto T,Torigoe T,Nishimura M. CD8 + tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resectionCancer Immunol ImmunotherYear: 2010591543154910.1007/s00262-010-0881-620567822|
|30..||Ishigami S,Arigami T,Uenosono Y,Matsumoto M,Okumura H,Uchikado Y,Kita Y,Nishizono Y,Maemura K,Kijima Y,Nakajo A,Owaki T,Ueno S,Hokita S,Natsugoe S. Cancerous HLA class I expression and regulatory T cell infiltration in gastric cancerCancer Immunol ImmunotherYear: 2012611663166910.1007/s00262-012-1225-522374482|
|31..||Disis ML,Goodell V,Schiffman K,Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patientsJ Clin ImmunolYear: 20042457157810.1023/B:JOCI.0000040928.67495.5215359116|
|32..||Wierecky J,Müller MR,Wirths S,Halder-Oehler E,Dörfel D,Schmidt SM,Häntschel M,Brugger W,Schröder S,Horger MS,Kanz L,Brossart P. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patientsCancer ResYear: 2006665910591810.1158/0008-5472.CAN-05-390516740731|
|33..||Saenger YM,Li Y,Chiou KC,Chan B,Rizzuto G,Terzulli SL,Merghoub T,Houghton AN,Wolchok JD. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanomaCancer ResYear: 2008689884989110.1158/0008-5472.CAN-08-223319047169|
|34..||Disis ML,Wallace DR,Gooley TA,Dang Y,Slota M,Lu H,Coveler AL,Childs JS,Higgins DM,Fintak PA,dela Rosa C,Tietje K,Link J,Waisman J,Salazar LG. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancerJ Clin OncolYear: 2009274685469210.1200/JCO.2008.20.678919720923|
Keywords: Keywords Intratumoral peptide injection, Antigen, Immunotherapy, Cytotoxic T lymphocyte.
Previous Document: Soluble Conjugated Microporous Polymers.
Next Document: TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4(+)CD25 (+) Treg apoptosis.